Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.64 |
| ▸ | VSIR | Q9H7M9 | 8/20 | 0.56 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945806 | 0.93 | S1PR1 (0.72) | S1PR1S1PR3VSIR | |
| SCHEMBL2941914 | 0.91 | S1PR1 (0.76) | S1PR1S1PR3VSIRPDCD1CD274 | |
| SCHEMBL2946166 | 0.88 | S1PR1 (0.67) | S1PR1S1PR3VSIRPDCD1CD274 | |
| SCHEMBL13233753 | 0.87 | S1PR1 (0.68) | S1PR1S1PR3VSIR | |
| SCHEMBL27638523 | 0.87 | S1PR1 (0.51) | S1PR1S1PR3VSIRPDCD1CD274 | |
| SCHEMBL2945276 | 0.87 | S1PR1 (0.50) | S1PR1S1PR3VSIRPDCD1CD274 | |
| SCHEMBL2946159 | 0.87 | S1PR1 (0.60) | S1PR1S1PR3VSIRPDCD1CD274 | |
| SCHEMBL2942715 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3VSIRPDCD1CD274 | |
| SCHEMBL2944557 | 0.86 | S1PR1 (0.57) | S1PR1S1PR3VSIRPDCD1CD274 | |
| SCHEMBL2950004 | 0.85 | VSIR (0.56) | S1PR1S1PR3VSIRPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750021-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2010-07-06 | — | — | US | claimed |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-05-21 | — | — | US | claimed |
| CN-1791592-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2006-06-21 | — | — | CN | claimed |
| EP-1628967-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-01 | — | — | EP | claimed |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2005-01-20 | — | — | US | claimed |
| WO-2005000833-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2005-01-06 | — | — | WO | claimed |
| US-7750021-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-7750021-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-7750021-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-05-21 | — | — | US | disclosed |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-05-21 | — | — | US | disclosed |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-05-21 | — | — | US | disclosed |
| US-7417065-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-08-26 | — | — | US | disclosed |
| US-7417065-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-08-26 | — | — | US | disclosed |
| US-7417065-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-08-26 | — | — | US | disclosed |
| EP-1628967-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-01 | — | — | EP | disclosed |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2005000833-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014725-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885VSIR 640/4885 |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885VSIR 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.